Applied Filters
J&J unit primed for multi-million dollar damages over counterfeits
Judge urges $18m award in ‘horrific’ counterfeiting case | Counterfeits were ‘bacterially contaminated’ | Ethicon.
Medtech firm faces lawsuit over COVID–19 design
Leading healthcare tech company accused of infringing COVID-19 test design | Cellex has asked court for injunctive relief | Siemens.
Medical device companies settle spinal therapy disputes
Nevro sued over the launch of a 10kHz spinal cord stimulation system | Boston Scientific negotiates a worldwide, non-exclusive, non-transferable licence.
Federal Circuit affirms US university’s patent invalidations
Kidney test patents detect “natural phenomena” | Delaware court grants Natera and Eurofins summary judgments on ineligibility.
Bad news for Italy’s EMA relocation challenge
EU’s top court denies bid that Amsterdam decision was a “misuse of powers” | Complaint said The Netherlands facility wasn’t ready | Milan lost out after random pick from a fish bowl.
Microsoft’s AI software unit shakes off patent suit
A Delaware court found in favour of the AI company, which Microsoft bought for $16 billion last year.
Swiss big pharma settles patent dispute with Insulet
The dispute over a patent covering a blood glucose level monitor ends with a multimillion-dollar payment and a licence agreement.
CleveMed sues ResMed over patent infringement
Ohio-based Cleveland Medical Devices (CleveMed) has accused ResMed of infringing patents through the sale of devices and software for the testing and treatment of sleep-disordered breathing or apnea.
Beckman Coulter loses late-stage bid to pause infringement proceedings
The US District Court for the District of Delaware has denied a motion from Beckman Coulter to stay an patent infringement lawsuit involving Sysmex Corporation until parallel proceedings at the US Court of Appeals for the Federal Circuit are concluded.
BGI wins $333m in DNA patent suit with Illumina
Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
